BioPharma Dive

Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

Eli Lilly cuts price of diabetes, weight-loss drugs in Canada, Globe and Mail reports

Eli Lilly is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada ...

Where Will Eli Lilly Be in 10 Years?

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Mounjaro Maker Eli Lilly Improves In Quality As BofA Sees 'Room For Stock Upside' With $3 Billion In Sales By 2026Mounjaro Maker Eli Lilly Improves In Quality As Bof…

Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.

Eli Lilly or Merck: Where Should Investors Put Their Money?

LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.

Judge Trims Lilly Suit Over Mass Produced Copycat Obesity Drugs

A federal judge allowed some of Eli Lilly & Co.‘s claims to proceed that allege a Texas-based compounding pharmacy violated ...

Eli Lilly's Obesity Drug Dominance Still Underpriced By Market, Bank of America Says

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as ...

Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade)

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...